Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on November 20, 2014. The filing details a significant corporate transaction: the agreement to acquire a controlling interest in Omega Pharma Invest NV ("Omega"). The transaction was previously announced on November 12, 2014, and the Share Purchase Agreement was dated November 6, 2014.
Key Financial Metrics and Transaction Details
The filing outlines the financial structure of the proposed acquisition of Omega, which involves the purchase of 685,348,257 shares, representing 95.77% of Omega's issued and outstanding share capital. The remaining shares will be held by Omega as treasury shares.
- Acquisition Consideration: The total consideration consists of cash and equity.
- Cash Consideration: EUR 1,845,983,131 to be paid to the sellers (Alychlo NV and Holdco I BE NV).
- Non-Cash Consideration: 5,397,711 shares of Perrigo Company plc to be issued to Alychlo.
- Debt Assumption: Perrigo will assume or repay/redeem all outstanding indebtedness of Omega and its subsidiaries.
- Interest Adjustment: The consideration will be increased by interest calculated on EUR 2.48 billion from September 30, 2014, until the completion date, starting at a rate of 5% with potential monthly increases.
Material Changes and Financing
The acquisition is expected to close during the third quarter of Perrigo's fiscal 2015, subject to closing conditions. The transaction represents a material change in the company's capital structure and operations. The cash portion of the deal will be financed through:
- Borrowings under existing credit facilities.
- An issuance of equity (the "Equity Offering").
- Borrowings under a bridge facility (the "Bridge Financing") or other debt issuances.
The filing incorporates unaudited pro forma condensed consolidated financial statements (Exhibit 99.1) that model the impact of the acquisition, the equity offering, and the bridge financing as if they had occurred on September 27, 2014 (balance sheet) and June 30, 2013 (statements of operations).
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance on revenue or earnings growth post-acquisition, other than the expectation of closing in the third quarter of fiscal 2015. The transaction is contingent upon the satisfaction or waiver of certain closing conditions. The filing notes that the pro forma statements give effect to the acquisition of Omega as well as the prior acquisition of Elan Corporation, plc (completed December 18, 2013).
Key Facts for Investor Verification
- Pro Forma Financials: Review Exhibit 99.1 for the unaudited pro forma balance sheet and statements of operations to understand the projected leverage and earnings impact.
- Financing Execution: Verify the successful completion of the Equity Offering and Bridge Financing required to fund the EUR 1.85 billion cash consideration.
- Closing Conditions: Monitor the satisfaction of regulatory and other closing conditions required to finalize the deal in Q3 fiscal 2015.
- Debt Load: Assess the total indebtedness of Omega to be assumed, as this is not explicitly quantified in the text of this filing.
- Interest Accrual: Note the variable interest component on the EUR 2.48 billion base, which will increase the total cost of the acquisition based on the time to closing.